Download Free Frontiers In Anti Cancer Drug Discovery Book in PDF and EPUB Free Download. You can read online Frontiers In Anti Cancer Drug Discovery and write the review.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an ebook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the ebook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The second volume of this series features 8 chapters that cover a variety of topics including: -treatment of multiple sclerosis and schizophrenia -neurochemistry of tremors -relationship between GABA and Alzheimer’s disease therapy -relationship between neurological diseases and cancer -research on angiogenesis-related blindness
Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The eighth volume of the book features reviews on these topics: - Key data management elements in clinical trials for oncological therapeutics - Prospects for therapeutic targeting of microRNAs in brain tumors - Breast cancer vaccines: current status and future approach - Desmocollin-3 and cancer - MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53 - Towards targeted therapy: anticancer agents targeting cell organelle mitochondria - Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults.
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development
Anticancer Agents: Frontiers in Cancer Chemotherapy describes cutting-edge approaches in the development of anticancer agents for chemotherapy.
Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them.
Topics in Anti-Cancer Research covers new developments in the field of cancer. Novel drugs as anticancer agents include natural and synthetic phenazines and other anti-cancer compounds. It also encompasses the role of estrogen as endocrine disruptors and strategies targeting cancer stem cells for the treatment of different types of cancers, including myeloma and renal cell cancer. The diversity of researches and topics published in this eBook Series will be valuable to cancer researchers, clinicians, and cancer professionals aiming to develop novel anti-cancer targets for the treatment of various cancers. The topics covered in the eighth volume of this series are as follows: -Novel Drugs for Multiple Myeloma -Synthetic Estrogens are Endocrine Disruptors via Inhibition of AF1 Domain of ERs -Recent Progress of Phenazines as Anticancer Agents -Cancer Stem Cell Targeting for Anticancer Therapy: Strategies and Challenges
The evidence of cancer in humans, animals and plant species suggests that it is as old as multicellular life on Earth. Why is it so difficult to understand and fight? Because cancer begins from the organism's own mutated single cell focused on its own survival. It would be naive to expect that cancer could be ever entirely eliminated, but there is still hope for finding effective treatments. The book is to give a view of selected aspects of cancer like its spread in nature, novel anticancer drugs based on Chinese herbs or birch bark, novel promising targets of annexins and kinases and progress in immunotherapy. It is our hope that you will find in this book interesting, inspiring and stimulating information concerning cancer research.
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
“Frontiers in Anti-Cancer Drug Discovery” is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The fifth volume of the series features chapters on the following topics: -Nutraceuticals and natural food products for cancer treatment -Pharmacogenomics in Anti-cancer treatment -Cancer stem cells -Potassium channel targeting for brain tumor treatment -Sorafenib in the management of hepatocellular carcinoma …and more.
Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.